TY - JOUR A1 - Buck, Andreas A1 - Decristoforo, Clemens T1 - Highlights lecture EANM 2015: the search for nuclear medicine's superheroes JF - European Journal of Nuclear Medicine and Molecular Imaging N2 - The EANM 2015 Annual Congress, held from October 10th to 14th in Hamburg, Germany, was outstanding in many respects. With 5550 participants, this was by far the largest European congress concerning nuclear medicine. More than 1750 scientific presentations were submitted, with more than 250 abstracts from young scientists, indicating that the future success of our discipline is fuelled by a high number of young individuals becoming involved in a multitude of scientific activities. Significant improvements have been made in molecular imaging of cancer, particularly in prostate cancer. PSMA-directed PET/CT appears to become a new gold standard for staging and restaging purposes. Novel tumour specific compounds have shown their potential for target identification also in other solid neoplasms and further our understanding of tumour biology and heterogeneity. In addition, a variety of nuclear imaging techniques guiding surgical interventions have been introduced. A particular focus of the congress was put on targeted, radionuclide based therapies. Novel theranostic concepts addressing also tumour entities with high incidence rates such as prostate cancer, melanoma, and lymphoma, have shown effective anti-tumour activity. Strategies have been presented to improve further already established therapeutic regimens such as somatostatin receptor based radio receptor therapy for treating advanced neuroendocrine tumours. Significant contributions were presented also in the neurosciences track. An increasing number of target structures of high interest in neurology and psychiatry are now available for PET and SPECT imaging, facilitating specific imaging of different subtypes of dementia and movement disorders as well as neuroinflammation. Major contributions in the cardiovascular track focused on further optimization of cardiac perfusion imaging by reducing radiation exposure, reducing scanning time, and improving motion correction. Besides coronary artery disease, many contributions focused on cardiac inflammation, cardiac sarcoidosis, and specific imaging of large vessel vasculitis. The physics and instrumentation track included many highlights such as novel, high resolution scanners. The most noteworthy news and developments of this meeting were summarized in the highlights lecture. Only 55 scientific contributions were mentioned, and hence they represent only a brief summary, which is outlined in this article. For a more detailed view, all presentations can be accessed by the online version of the European Journal of Nuclear Medicine and Molecular Imaging (Volume 42, Supplement 1). KW - Conjugate arc therapy KW - Phase-II KW - 18F-FDG PET/CT KW - Highlights Lecture KW - Molecular Imaging KW - Prostate-cancer KW - Radionuclide therapy KW - Myocardial perfusion KW - Preclinical evaluation KW - Targeted therapy KW - Thyroid cancer KW - SPECT KW - 2015 KW - EANM KW - Hamburg KW - Physics and instrumentation KW - Radiopharmacy KW - Oncology KW - Radionuclide Therapy KW - Cardiology KW - Neurosciences Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187613 VL - 43 IS - 10 ER - TY - THES A1 - Hefner, Jochen T1 - Psychotherapeutische Interventionen bei Krebskranken : Analyse der Ergebnisse psychoonkologischer Interventionsstudien. T1 - Psychotherapeutic Interventions for patients with malignant dieseases.Analysis of the results from psychooncological Interventions. N2 - Diese Arbeit soll der Bestandsaufnahme dienen, inwieweit psychotherapeutische Interventionen dazu beitragen können, das Betreuungsangebot von Tumorpatienten zu ergänzen. In erster Linie wird dabei der Frage nachgegangen, ob diese Interventionen geeignet sind, die Lebensqualität der Betroffenen zu verbessern. Da bereits seit dem Beginn psycho-onkologischer Forschung diskutiert wurde, ob psychische Einflussfaktoren und entsprechende Interventionen nicht auch den Krankheitsverlauf bei Krebs mitbestimmen können, soll auch dieser Aspekt aus aktueller Sicht heraus beleuchtet werden. Schließlich soll darauf eingegangen werden, ob psychotherapeutische Interventionen für Tumorpatienten gerade in modernen Gesellschaften mit ihren kostspieligen Gesundheitssystemen eine sinnvolle Ergänzung des medizinischen Betreuungsangebotes für alle Beteiligten darstellen können. Im Zusammenhang dieser Arbeit werden darunter einerseits das maximale Ausnutzen vorhandener schulmedizinischer Strukturen und andererseits ein möglicher Kostenvorteil durch die Kombination schulmedizinischer und psychosomatischer Therapien verstanden. N2 - In this paper, the rationale for psychotherapeutic interventions for cancer patients is discussed. First, the issue of possible beneficial effects of these interventions for the patient´s quality of life will be adressed. Since there is much debate about the probable influence of such interventions on the course of malignant diseases, this point will be examined seperately. Finally the question of enhancing medical supply of cancer patients within modern helthcare systems is elaborated. KW - Psychoonkologie KW - Psychotherapeutischer Prozess KW - Klinische Psychotherapie KW - Psychotherapeutische Versorgung KW - Psychotherapie KW - Onkologie KW - Krebsforsc KW - Psychooncology KW - Oncology KW - Psychotherapy KW - Psychoneuroimmunology Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-24010 ER - TY - THES A1 - Jendretzki, Julia Bianca T1 - Ernährungsberatung in der Onkologie – Eine Fragebogen-basierte Analyse zur Erfassung des subjektiven und medizinischen Beratungsbedarfs von krebskranken Patienten am Comprehensive Cancer Center der Uniklinik Würzburg T1 - Nutritional counseling in oncology - A questionnaire-based analysis to assess the subjective and medical counseling needs of patients with cancer at the Comprehensive Cancer Center of Würzburg University Hospital N2 - Hintergrund Mangelernährung bleibt im klinischen Alltag noch oft unerkannt und wird häufig unterschätzt. Die durchgeführte Studie hatte das Ziel, die Häufigkeit eines Ernährungsrisikos sowie die Patientengruppen, welche am meisten von einer Ernährungsberatung profitieren würden, zu ermitteln. Methode Ambulant versorgte Patienten mit Tumorerkrankungen des Universitätsklinikums Würzburgs wurden mittels eines vom Ernährungsteam des Comprehensive Cancer Centers erstellten Fragebogens zwischen Mai 2017 und Januar 2018 befragt. Es wurden insbesondere Fragen zum Ernährungszustand und Ernährungsproblemen gestellt. Zudem wurde das Risiko für das Entstehen einer Mangelernährung mittels des validierten Screening-Fragebogens Malnutrition Universal Screening Tool (MUST) erfasst. Ergebnisse In der vorliegenden Studie wurden 311 Patienten befragt. Im MUST-Screening zeigte sich bei 16,4 % ein mittleres und bei 20,3 % ein hohes Risiko für eine Mangelernährung, wobei die Punktevergabe in 94,8 % der Fälle durch einen ungewollten Gewichtsverlust erfolgte. Insbesondere Patienten der Gastroenterologie sowie Patienten > 65 Jahre wiesen ein hohes Risiko auf. Es zeigte sich ein signifikanter Zusammenhang zwischen stattgehabter Chemotherapie und einem MUST-Score ≥ 2 (OR = 3,6). Als besondere Risikofaktoren ließen sich zudem Geschmackveränderungen, Schluckbeschwerden, Ekelempfinden und Appetitlosigkeit feststellen (OR = 2,3 – 3,2). Interesse am Thema „Ernährung bei Krebs“ zeigten vor allem junge, weibliche und normalgewichtige Patienten. Ein Gespräch mit dem behandelten Arzt hierzu fand nur bei 38 % aller Patienten statt. Schlussfolgerungen Jeder fünfte Patient unterlag einem hohen Ernährungsrisiko, nur ein Bruchteil wäre durch Erhebung des Body Mass Index aufgefallen. Ein valides Screeningverfahren mit aussagekräftigen Parametern sollte Einzug in den klinischen Alltag ambulant versorgter Krebspatienten finden und gemeinsam mit einer Ernährungsberatung standardisiert bei Diagnosestellung sowie in regelmäßigen Abständen im Verlauf stattfinden. N2 - Background Malnutrition still often remains unrecognized in clinical practice and is frequently underestimated. The aim of this study was to determine the frequency of nutritional risk and the patient groups that would benefit most from nutritional counseling. Methods Outpatients with tumor diseases at the University Hospital of Würzburg were surveyed using a questionnaire prepared by the Comprehensive Cancer Center's nutrition team between May 2017 and January 2018. In particular, questions were asked about nutritional status and nutritional problems. In addition, the risk of developing malnutrition was assessed using the validated screening questionnaire Malnutrition Universal Screening Tool (MUST). Results In the present study, 311 patients were interviewed. MUST screening showed 16.4% to be at moderate risk of malnutrition and 20.3% to be at high risk of malnutrition, with scoring by unintentional weight loss in 94.8% of cases. Gastroenterology patients and patients > 65 years of age were at particularly high risk. There was a significant association between chemotherapy given and a MUST score ≥ 2 (OR = 3.6). In addition, changes in taste, difficulty swallowing, disgust, and loss of appetite could be identified as particular risk factors (OR = 2.3 - 3.2). Interest in the topic of "nutrition in cancer" was mainly shown by young, female and normal-weight patients. A discussion with the treating physician on this topic took place in only 38% of all patients. Conclusions One in five patients was at high nutritional risk, only a fraction would have been detected by body mass index. A valid screening procedure with meaningful parameters should be introduced into the clinical routine of outpatient cancer patients and, together with nutritional counseling, should take place in a standardized manner at the time of diagnosis and at regular intervals during the course of treatment. Translated with www.DeepL.com/Translator (free version) KW - Ernährungsberatung KW - Mangelernährung KW - Onkologie KW - Ambulante Patienten KW - MUST-Score KW - Nutritional Counseling KW - Oncology KW - Outpatients KW - MUST-Score KW - Malnutrition Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-283495 ER - TY - JOUR A1 - Jurowich, Christian A1 - Lichthardt, Sven A1 - Kastner, Caroline A1 - Haubitz, Imme A1 - Prock, Andre A1 - Filser, Jörg A1 - Germer, Christoph-Thomas A1 - Wiegering, Armin T1 - Laparoscopic versus open right hemicolectomy in colon carcinoma: A propensity score analysis of the DGAV StuDoQ|ColonCancer registry JF - PLoS ONE N2 - Objective To assess whether laparoscopy has any advantages over open resection for right-sided colon cancer. Summary background data Right hemicolectomy can be performed using either a conventional open or a minimally invasive laparoscopic technique. It is not clear whether these different access routes differ with regard to short-term postoperative outcomes. Methods Patients documented in the German Society for General and Visceral Surgery StuDoQ|ColonCancer registry who underwent right hemicolectomy were analyzed regarding early postoperative complications according to Clavien-Dindo (primary endpoint), operation (OP) time, length of postoperative hospital stay (LOS), MTL30 and number of lymph nodes retrieved (secondary endpoints). Results A total of 4.997 patients were identified as undergoing oncological right hemicolectomy without additional interventions. Of these, 4.062 (81.3%) underwent open, 935 (18.7%) laparoscopic surgery. Propensity score analysis showed a significantly shorter LOS (OR: 0.55 CI 95%0.47-.64) and a significantly longer OP time (OR2.32 CI 1.98–2.71) for the laparoscopic route. Risk factors for postoperative complications, anastomotic insufficiency, ileus, reoperation and positive MTL30 were higher ASA status, higher age and increasing BMI. The surgical access route (open / lap) had no influence on these factors, but the laparoscopic group did have markedly fewer lymph nodes retrieved. Conclusion The present registry-based analysis could detect no relevant advantages for the minimally invasive laparoscopic access route. Further oncological analyses are needed to clarify the extent to which the smaller lymph node harvest in the laparoscopic group is accompanied by a poorer oncological outcome. KW - Laparoscopy KW - Lymph nodes KW - Minimally invasive surgery KW - Surgical oncology KW - Oncology KW - Surgical and invasive medical procedures Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-202184 VL - 14 IS - 6 ER - TY - THES A1 - Stowasser, Christian T1 - Mangelernährung und Appetitlosigkeit bei Patienten mit metastasierter oder rezidivierter Tumorerkrankung T1 - Malnutrition and loss of appetite in patients with metastasized or relapsed cancer N2 - Mangelernährung und Appetitlosigkeit werden trotz zunehmender Forschung noch in ihren Auswirkungen auf Patienten und Gesundheitssystem unterschätzt. Um dem entgegenzuwirken, sind zusätzliche Informationen zu Risikofaktoren, Auswirkungen und zu einem adäquaten Screening beider Symptome vonnöten. Diese Untersuchung geht der Frage nach, ob die Erfassung der Appetitlosigkeit auch ein geeignetes Verfahren zur Einschätzung des Mangelernährungsrisikos darstellt. Zusätzlich wurden die Patienten auf Risikofaktoren und Auswirkungen von Mangelernährung und Appetitlosigkeit hin untersucht. Dazu wurden bei den Patienten unter anderem soziodemographische Daten, ein NRS-2002 Vorscreening und die per ESAS erfasste Symptomlast statistisch ausgewertet. Diese waren zuvor im Rahmen des BUKA Projekts an der Universität Würzburg ermittelt worden. Von den 486 geeigneten Patienten konnten 477 in die Untersuchung eingeschlossen werden. Davon zeigten 65.6% ein erhöhtes Mangelernährungsrisiko und 31.2% eine manifeste Appetitlosigkeit. Der Allgemeinzustand und die Lebensqualität beider Gruppen waren signifikant eingeschränkt. Zusätzlich wiesen sie eine deutlich erhöhte Symptombelastung im ESAS auf. Als unabhängige Risikofaktoren für Mangelernährung konnten der BMI, der Allgemeinzustand (ECOG Status), die Tumorlokalisation und der Appetitstatus eruiert werden. Bei der Appetitlosigkeit traf dies auf den ECOG Status, das Alter und das NRS Vorscreening zu. Die Bestimmung der Appetitlosigkeit erwies sich als nicht ausreichend präzise, um auch das Mangelernährungsrisiko zu erfassen. Insgesamt wurden 61.4% der Patienten übereinstimmend getestet. Die Wahrscheinlichkeit bei erhöhtem Mangelernährungsrisiko (NRS Vorscreening positiv) auch eine manifeste Appetitlosigkeit (ESAS Appetitverlust>3) aufzuweisen betrug nur 44%. Andererseits aber zeigten Patienten mit manifester Appetitlosigkeit in 94% auch ein erhöhtes Mangelernährungsrisiko. Der Einfluss von BMI, Tumorlokalisation und Appetitverlust zeigte sich hierbei signifikant auf die Chance übereinstimmend getestet zu werden. In der Zusammenschau betonen die Ergebnisse unserer Untersuchung die Wichtigkeit einer präzisen Erfassung von Appetitlosigkeit und Mangelernährung bei Tumorpatienten, auch in der Palliativmedizin. Besonders vor dem Hintergrund einer alternden Gesellschaft mit wahrscheinlich zunehmender Inzidenz und Prävalenz von Tumorerkrankungen gewinnen Erkennung und Therapie von Mangelernährung und Appetitlosigkeit zusätzlich an Bedeutung.   N2 - Despite increasing research, malnutrition and loss of appetite are still underestimated in their effects on patients and the health system. To counteract this, additional information on risk factors, effects and adequate screening of both symptoms is required. This investigation examines the question of whether the detection of anorexia is also a suitable method for assessing the risk of malnutrition. In addition, the patients were examined for risk factors and effects of malnutrition and loss of appetite. For this purpose, socio-demographic data, an NRS-2002 pre-screening and the symptom burden recorded by ESAS were statistically evaluated. These had previously been determined as part of the BUKA project at the University of Würzburg. Of the 486 eligible patients, 477 were included in the study. Of these, 65.6% showed an increased risk for malnutrition and 31.2% loss of appetite. The general condition and quality of life of both groups were significantly reduced. In addition, they showed a significantly increased symptom burden in the ESAS. The BMI, general condition (ECOG status), tumor location and appetite status were identified as independent risk factors for malnutrition. In the case of anorexia, this applied to the ECOG status, age and the result of the NRS pre-screening. The determination of anorexia turned out to be not sufficiently precise to also record the malnutrition risk. A total of 61.4% of the patients were tested consistently. The likelihood of anorexia (ESAS loss of appetite> 3) in patients with an increased risk for malnutrition (NRS screening positive) was only 44%. On the other hand, patients with anorexia also showed an increased risk of malnutrition in 94%. The influence of BMI, tumor localization and loss of appetite was shown to be significant in the chance of being tested in agreement. In summary, the results of our investigation emphasize the importance of a precise assessment of anorexia and malnutrition in tumor patients, also in palliative medicine. Particularly in the context of an aging society with a likely increase in the incidence and prevalence of tumor diseases, the detection and therapy of malnutrition and anorexia are becoming increasingly important. KW - Palliativmedizin KW - Mangelernährung KW - Appetitlosigkeit KW - Tumor KW - Universitätsklinikum Würzburg KW - Tumorpatienten KW - Malnutrition KW - Anorexia KW - Oncology KW - NRS-2002 KW - Palliative Medicine Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-205122 ER - TY - JOUR A1 - Werner, Rudolf A1 - Solnes, Lilja A1 - Javadi, Mehrbod A1 - Weich, Alexander A1 - Gorin, Michael A1 - Pienta, Kenneth A1 - Higuchi, Takahiro A1 - Buck, Andreas A1 - Pomper, Martin A1 - Rowe, Steven A1 - Lapa, Constantin T1 - SSTR-RADS Version 1.0 as a Reporting System for SSTR-PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework JF - Journal of Nuclear Medicine N2 - Reliable standards and criteria for somatostatin receptor (SSTR) positron emission tomography (PET) are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR-PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors (NET). SSTR-RADS could guide the imaging specialist in interpreting SSTR-PET scans, facilitate communication with the referring clinician so that appropriate work-up for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned Peptide Receptor Radionuclide Therapy. KW - Radionuclide Therapy KW - Standardisierung KW - Positronen-Emissions-Tomografie KW - 68Ga-DOTATATE/-TOC KW - Gastrointestinal KW - Neuroendocrine KW - Neuroendocrine Tumor KW - Oncology KW - GI KW - PET KW - PET/CT KW - PRRT KW - RADS KW - SSTR Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161298 SN - 0161-5505 N1 - This research was originally published in JNM. Rudolf A. Werner, Lilja B. Solnes, Mehrbod Som Javadi, Alexander Weich, Michael A. Gorin, Kenneth J. Pienta, Takahiro Higuchi, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe, Constantin Lapa. SSTR-RADS Version 1.0 as a Reporting System for SSTR-PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J. Nucl. Med. July 1, 2018, vol. 59, no. 7, 1085-1091. © SNMMI ER -